Fig. 2: Anti-tumor efficacy induced by G100–ZVex combination is dependent on CD8 T cells. | npj Vaccines

Fig. 2: Anti-tumor efficacy induced by G100–ZVex combination is dependent on CD8 T cells.

From: Intratumoral immune activation with TLR4 agonist synergizes with effector T cells to eradicate established murine tumors

Fig. 2

Female C57BL/6 mice (n = 10–15/group) were inoculated with B16/OVA cells (flank, subcutaneously) on day 0. On day 4, mice were given intraperitoneal administration of depletion antibodies as labeled in the figure. Once tumors became palpable (averaged 5 mm in diameter), mice were immunized once with ZVex/OVA and administered intratumoral G100 that was continued twice weekly until observation of complete tumor regression or euthanized due to tumor burden. a Tumor size and b survival were monitored and recorded at least 2–3 times weekly. Tumor sizes were plotted as average tumor volume ± SEM. Death was recorded as a result of death defined by euthanasia criteria. Data are representative of at least two independent experiments (****p < 0.0001).

Back to article page